

On the mechanism of inter-kingdom signalling - synthesis of isotope labelled *N*-acyl-L-homoserine lactones (AHLs)


Dorota Jakubczyk^{a,b}, Stefan Bräse^a, Gerald Brenner-Weiß^b

^a Karlsruhe Institute of Technology, Institut für Organische Chemie, Fritz-Haber-Weg 6, 76131 Karlsruhe, Germany, E-mail: dorota.jakubczyk@kit.edu

^b Karlsruhe Institute of Technology, Institut für Funktionelle Grenzflächen, Hermann von Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany

Introduction

N-acyl-L-homoserine lactones **1** (AHLs) are natural products which



belong to **semiochemicals** (signal molecules or infochemical compounds). They act as messengers within (**pheromones**) or between (**allomones**) species.

AHLs are so-called autoinducer molecules, enabling inter-bacterial communication (**Quorum Sensing**) and inter-kingdom communication (**Inter-kingdom Signalling**).

Inter-bacterial communication - biofilm formation

Biofilm - an aggregate of microorganisms (Fig. 1-3)

- Common cause of persistent infections
- Chronic, destructive inflammatory processes
- Antibiotic resistant



Fig. 1. Biofilm



Fig. 2. Biofilm





Fig. 3. Occurrence of biofilm

Inter-kingdom Signalling – communication between Prokaryotes and Eukaryotes



U.S. National Library of Medicine

Fig. 4. Apoptosis of the cell

Interactions of bacteria with a variety of mammalian cells:

- Induction of apoptosis (Fig. 4)
- Induction of the chemotaxis of neutrophils (Fig. 5,6)




Fig. 5. Chemotaxis of neutrophils





Fig. 6. Migration of human polymorphonuclear neutrophils (PMN) toward increasing concentrations of AHLs with vary chain length.

Aim


Synthesis and isotopic labelling of *N*-acyl-L-homoserine lactones - detection of AHLs crossing eukaryotic cell membranes



Elucidating the mechanism of Inter-kingdom Signalling

Results and discussion

Synthesis of a highly biologically active, deuterium and tritium labelled *N*-(3-oxododecanoyl)-L-homoserine lactone (scheme 1).




Scheme 1. a) 4-Dimethylaminopyridine (DMAP); 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC); CH_2Cl_2 ; RT; b) L-homoserine lactone hydrobromide, Et_3N ; CH_3CN ; RT-80° C; c) Ethylene glycol, *p*-TsOH, $\text{CH}(\text{OMe})_3$, PhMe, 110° C-RT; d) $\text{Pd}(\text{OAc})_2$, THF, CH_3COOH , MeOH, NaBR_4 , NaOH_{aq} , -196° C – RT; e) HClO_4 , CH_2Cl_2 , 0° C-RT; R = D or T; Y = yield (see Table 1).

Unconventional conditions of the reaction (Fot. 1, 2, 3).



Fot. 1. Reaction starts in the liquid nitrogen.



Fot. 2. Agitation in a room temperature.




Fot. 3. Reduced palladium residue.

Step d									
Entry	R	Time [h]	Additives notes	Other deuterated reagents	Yield [%]	D content ^a at preterminal C atom [%]	D content ^a at terminal C atom [%]	Isomers ^b	Specific radioactivity ^c [mCi/mmol]
1	D	16	NaBD_4	-	65	45-60	99	[M+(1-6)+H ⁺] [M-(1,2)+H ⁺]	-
2	D	16,5	Excess of NaBD_4	1M NaOD (30% NaOD in D_2O diluted in MeOH)	79	90	99	[M+(1,2)+H ⁺] [M-(1,2)+H ⁺]	-
3	T	16	NaBT_4	-	78	-	-	[M+1+H ⁺] [M-1+H ⁺]	588,5

Table 1. Results for the synthesis of the deuterium and tritium labelled *N*-(3-oxododecanoyl)-L-homoserine lactones; ^a Determined by ¹H NMR and mass spectrometry. ^b Determined by ESI-TOF MS. ^c Determined by Liquid Scintillation counter.

Work with tritium - the radioactive isotope (Fot. 4, 5, 6).



Fot. 4. Sodium borotritide (NaBT_4).



Fot. 5. Preparative thin layer chromatography.



Fot. 6. Scintillation counter - measurement of radioactivity.

Conclusions

- The new methods of isotopic labelling of AHL was developed. The methods are efficient and enable further biological investigations;
- Structures of the products were confirmed by TLC, ¹H NMR, ¹³C NMR, ESI-TOF MS, HRMS, IR and Raman spectroscopy, TLC / autoradiography and Liquid Scintillation Counter.

References

- [1] Schwarzmann, G. *Biochim. Biophys. Acta* **1978**, 529, 106;
- [2] Chhabra, S. R.; Stead, P.; Bainton, N. J.; Salmond, G. P. C.; Stewart, G. S. A. B.; Williams, P.; Bycroft, B. W. *J. Antibiot.* **1993**, 46, 441;
- [3] Costerton J. W., Stewart Philip S., Greenberg E. P., *Science*, **1999**, 284(5418), 1318 – 1322;
- [4] Chhabra, S. R., C. Hartly, et al., *Journal of Medicinal Chemistry*, **2003**, 46(1) 97-104.